The VEGF-Trap soluble decoy receptor (containing the second Ig-like domain of VEGFR1 and third Ig-like domain of VEGFR2 fused to a human IgG Fc) delivered via an rAAV serotype 2 through intravenous administration reduced not only the concentration of VEGF in the serum but also primary tumor growth, preventing pulmonary metastasis in breast cancer [170]. This evidence concerns the gene FLT1 and breast carcinoma.